The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer

Breast Neoplasms Clinical Trial

Official title:

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01942759
• Other study ID #: BC-PET-MR-01
• Status: Completed
• Phase: N/A
• First received: September 2, 2013
• Last updated: June 8, 2014
• Start date: September 2013
• Est. completion date: June 2014

Study information

• Verified date: June 2014
• Source: Bagcilar Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine findings of positron emission tomography and diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast cancer and compare of two imaging modality in these patients.

Description:

We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic value of these indexes in breast cancer in this study. The evaluated and compared parameters are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status, histologic grade, modified Nottingham prognostic index.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Newly diagnosis of breast cancer for which surgical intervention is planned

Exclusion Criteria:

• patients received neoadjuvant chemotherapy

• before breast surgery

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Breast Neoplasms

Locations

Country	Name	City	State
Turkey	Bagcilar Training and Research Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Bagcilar Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the relationships between both SUVmax and ADC and clinicopathological prognostic factors		3 years	No